{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T21:05:05Z","timestamp":1768251905817,"version":"3.49.0"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T00:00:00Z","timestamp":1566864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.01956","type":"journal-article","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T04:20:27Z","timestamp":1566879627000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Can Complementary Prime-Boost Immunization Strategies Be an Alternative and Promising Vaccine Approach Against Dengue Virus?"],"prefix":"10.3389","volume":"10","author":[{"given":"Iris","family":"Vald\u00e9s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Lazo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisset","family":"Hermida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Guill\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1zaro","family":"Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12916-017-0911-8","article-title":"The public health value of vaccines beyond efficacy: methods, measures and outcomes","volume":"15","author":"Wilder-Smith","year":"2017","journal-title":"BMC Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"218590","DOI":"10.1155\/2010\/218590","article-title":"Emerging vaccine informatics","volume":"2010","author":"He","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"12313","DOI":"10.1073\/pnas.1400475111","article-title":"Valuing vaccination","volume":"111","author":"Barnighausen","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B4","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/emmm.201403876","article-title":"Vaccines for the 21st century","volume":"6","author":"Delany","year":"2014","journal-title":"EMBO Mol Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/nrmicro2668","article-title":"The development of vaccines: how the past led to the future","volume":"9","author":"Plotkin","year":"2011","journal-title":"Nat Rev Microbiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.it.2003.11.009","article-title":"Jump-starting the immune system: prime-boosting comes of age","volume":"25","author":"Woodland","year":"2004","journal-title":"Trends Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Curr Opin Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.vaccine.2015.11.062","article-title":"Prime-boost vaccine strategy against viral infections: mechanisms and benefits","volume":"34","author":"Kardani","year":"2016","journal-title":"Vaccine"},{"key":"B9","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.micinf.2005.03.009","article-title":"Prime-boost immunisation strategies for tuberculosis","volume":"7","author":"McShane","year":"2005","journal-title":"Microbes Infect."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/cis238","article-title":"Nomenclature for immune correlates of protection after vaccination","volume":"54","author":"Plotkin","year":"2012","journal-title":"Clin Infect Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/S0140-6736(07)60645-X","article-title":"The burden of dengue infection","volume":"369","author":"Halstead","year":"2007","journal-title":"Lancet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"taw062","DOI":"10.1093\/jtm\/taw062","article-title":"Evidence-based risk assessment and communication: a new global dengue-risk map for travellers and clinicians","volume":"23","author":"Jentes","year":"2016","journal-title":"J Travel Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S0188-4409(02)00378-8","article-title":"The global emergence\/resurgence of arboviral diseases as public health problems","volume":"33","author":"Gubler","year":"2002","journal-title":"Arch Med Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/S0140-6736(07)61687-0","article-title":"Dengue","volume":"370","author":"Halstead","year":"2007","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S0140-6736(18)32560-1","article-title":"Dengue","volume":"393","author":"Wilder-Smith","year":"2019","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4659","DOI":"10.1016\/j.vaccine.2017.07.045","article-title":"Immune correlates of protection for dengue: state of the art and research agenda","volume":"35","author":"Katzelnick","year":"2017","journal-title":"Vaccine"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1016\/j.vaccine.2018.02.062","article-title":"Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines","volume":"36","author":"Vannice","year":"2018","journal-title":"Vaccine"},{"key":"B19","doi-asserted-by":"publisher","first-page":"a029520","DOI":"10.1101\/cshperspect.a029520","article-title":"Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? The challenges of a dengue vaccine","volume":"10","author":"Screaton","year":"2018","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e0004854","DOI":"10.1371\/journal.pntd.0004854","article-title":"Challenges to the design of clinical trials for live-attenuated tetravalent dengue vaccines","volume":"10","author":"Russell","year":"2016","journal-title":"PLoS Negl Trop Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1126\/science.aaq0215","article-title":"Advancing dengue vaccine development","volume":"358","author":"Feinberg","year":"2017","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/S1386-6532(09)70290-2","article-title":"Immunogenicity of sanofi pasteur tetravalent dengue vaccine","volume":"46","author":"Guy","year":"2009","journal-title":"J Clin Virol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"E2046","DOI":"10.1073\/pnas.1305227110","article-title":"Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells","volume":"110","author":"Weiskopf","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1093\/infdis\/jiw309","article-title":"HLA-DRB1 alleles are associated with different magnitudes of dengue virus-specific CD4+ T-cell responses","volume":"214","author":"Weiskopf","year":"2016","journal-title":"J Infect Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"a029462","DOI":"10.1101\/cshperspect.a029462","article-title":"Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? questions raised by the development and implementation of dengue vaccines: example of the sanofi pasteur tetravalent dengue vaccine","volume":"10","author":"Guy","year":"2018","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/S1473-3099(18)30494-8","article-title":"Deliberations of the strategic advisory group of experts on immunization on the use of CYD-TDV dengue vaccine","volume":"19","author":"Wilder-Smith","year":"2019","journal-title":"Lancet Infect Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"tay057","DOI":"10.1093\/jtm\/tay057","article-title":"Serostatus-dependent performance of the first licensed dengue vaccine: implications for travellers","volume":"25","author":"Wilder-Smith","year":"2018","journal-title":"J Travel Med."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/tay153","article-title":"What is the prospect of a safe and effective dengue vaccine for travelers?","author":"Durbin","year":"2019","journal-title":"J Travel Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1586\/14760584.2016.1115727","article-title":"Development of TV003\/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD vaccine?","volume":"15","author":"Whitehead","year":"2016","journal-title":"Exp Rev Vaccin."},{"key":"B31","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1586\/14760584.2016.1128328","article-title":"A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone","volume":"15","author":"Osorio","year":"2016","journal-title":"Exp Rev Vaccin."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1080\/21645515.2016.1276138","article-title":"Progress in HIV vaccine development","volume":"13","author":"Hsu","year":"2017","journal-title":"Hum Vaccin Immunother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"174378","DOI":"10.1155\/2010\/174378","article-title":"DNA vaccines: developing new strategies against cancer","volume":"2010","author":"Fioretti","year":"2010","journal-title":"J Biomed Biotechnol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1479-0556-7-7","article-title":"Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen","volume":"7","author":"Alekseeva","year":"2009","journal-title":"Genet Vaccines Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.4049\/jimmunol.170.5.2599","article-title":"Prime boost vaccination strategies: CD8 T cell numbers, protection, and Th1 bias","volume":"170","author":"Woodberry","year":"2003","journal-title":"J Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1073\/pnas.90.11.5214","article-title":"Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria","volume":"90","author":"Li","year":"1993","journal-title":"Proc Natl Acad Sci USA."},{"key":"B37","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.4049\/jimmunol.153.10.4636","article-title":"Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity","volume":"153","author":"Rodriguez","year":"1994","journal-title":"J Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2180-5-45","article-title":"Combined prime-boost vaccination against tick-borne encephalitis (TBE) using a recombinant vaccinia virus and a bacterial plasmid both expressing TBE virus non-structural NS1 protein","volume":"5","author":"Aleshin","year":"2005","journal-title":"BMC Microbiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1093\/infdis\/jit267","article-title":"A heterologous prime\/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus","volume":"208","author":"Fournillier","year":"2013","journal-title":"J Infect Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11262-014-1070-z","article-title":"Enhanced cell immune responses to hepatitis C virus core by novel heterologous DNA prime\/lambda nanoparticles boost in mice","volume":"49","author":"Saeedi","year":"2014","journal-title":"Virus Genes"},{"key":"B41","doi-asserted-by":"publisher","first-page":"5968","DOI":"10.1016\/j.vaccine.2007.05.052","article-title":"DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity","volume":"25","author":"Buonaguro","year":"2007","journal-title":"Vaccine."},{"key":"B42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.pep.2015.08.024","article-title":"VLP production in Leishmania tarentolae: a novel expression system for purification and assembly of HPV16 L1","volume":"116","author":"Bolhassani","year":"2015","journal-title":"Protein Expr Purif."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1586\/14760584.2016.1158108","article-title":"New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design","volume":"15","author":"Musich","year":"2016","journal-title":"Exp Rev Vaccines."},{"key":"B44","doi-asserted-by":"publisher","first-page":"8729","DOI":"10.1128\/JVI.77.16.8729-8735.2003","article-title":"Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines","volume":"77","author":"Barouch","year":"2003","journal-title":"J Virol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1093\/ije\/22.6.1154","article-title":"Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis","volume":"22","author":"Rodrigues","year":"1993","journal-title":"Int J Epidemiol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3389\/fimmu.2018.01796","article-title":"The profile of T cell responses in bacille calmette-guerin-primed mice boosted by a novel sendai virus vectored anti-tuberculosis vaccine","volume":"9","author":"Hu","year":"2018","journal-title":"Front Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.micpath.2016.01.006","article-title":"Recombinant BCG prime and PPE protein boost provides potent protection against acute Mycobacterium tuberculosis infection in mice","volume":"93","author":"Yang","year":"2016","journal-title":"Microb Pathog."},{"key":"B48","first-page":"200","article-title":"Does the efficacy of BCG decline with time since vaccination?","volume":"2","author":"Sterne","year":"1998","journal-title":"Int J Tuberc Lung Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0140-6736(96)02166-6","article-title":"Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1586\/erv.12.94","article-title":"Prime-boost approaches to tuberculosis vaccine development","volume":"11","author":"Dalmia","year":"2012","journal-title":"Exp Rev Vaccines."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1242\/jeb.00642","article-title":"Prime-boost strategies for malaria vaccine development","volume":"206","author":"Dunachie","year":"2003","journal-title":"J Exp Biol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1073\/pnas.1211248110","article-title":"Helicobacter pylori \u03b3-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune tolerance","volume":"110","author":"Oertli","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B53","doi-asserted-by":"publisher","first-page":"32299","DOI":"10.18632\/oncotarget.5869","article-title":"HSP60: a double edge sword in autoimmunity","volume":"6","author":"Landstein","year":"2015","journal-title":"Oncotarget."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/cid\/cit048","article-title":"Complex correlates of protection after vaccination","volume":"56","author":"Plotkin","year":"2013","journal-title":"Clin Infect Dis"},{"key":"B55","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.4049\/jimmunol.1401597","article-title":"CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice","volume":"193","author":"Zellweger","year":"2014","journal-title":"J Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/00001432-200210000-00003","article-title":"Dengue","volume":"15","author":"Halstead","year":"2002","journal-title":"Curr Opin Infect Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1089\/vim.2019.0044","article-title":"Effective dengue vaccine: a pipe dream?","volume":"32","author":"Gil","year":"2019","journal-title":"Viral Immunol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.4049\/jimmunol.1600927","article-title":"A tetravalent formulation based on recombinant nucleocapsid-like particles from dengue viruses induces a functional immune response in mice and monkeys","volume":"197","author":"Gil","year":"2016","journal-title":"J Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"B60","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.4049\/jimmunol.0801974","article-title":"A protective role for dengue virus-specific CD8+ T cells","volume":"182","author":"Yauch","year":"2009","journal-title":"J Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"5405","DOI":"10.4049\/jimmunol.1001709","article-title":"CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination","volume":"185","author":"Yauch","year":"2010","journal-title":"J Immunol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e1003723","DOI":"10.1371\/journal.ppat.1003723","article-title":"Role of humoral versus cellular responses induced by a protective dengue vaccine candidate","volume":"9","author":"Zellweger","year":"2013","journal-title":"PLoS Pathog."},{"key":"B63","doi-asserted-by":"publisher","first-page":"6494","DOI":"10.1128\/JVI.00036-15","article-title":"CD8+ T cells can mediate short-term protection against heterotypic dengue virus reinfection in mice","volume":"89","author":"Zellweger","year":"2015","journal-title":"J Virol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"420","DOI":"10.4269\/ajtmh.2001.65.420","article-title":"Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine","volume":"65","author":"Simmons","year":"2001","journal-title":"Am J Trop Med Hyg."},{"key":"B65","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1089\/vim.2005.18.709","article-title":"DNA priming E and NS1 constructs\u2013homologous proteins boosting immunization strategy to improve immune response against dengue in mice","volume":"18","author":"Mellado-Sanchez","year":"2005","journal-title":"Viral Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"9577","DOI":"10.1128\/JVI.00284-06","article-title":"Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques","volume":"80","author":"Simmons","year":"2006","journal-title":"J Virol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1472-6750-7-10","article-title":"An adenovirus prime\/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes","volume":"7","author":"Khanam","year":"2007","journal-title":"BMC Biotechnol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"11634","DOI":"10.1128\/JVI.00996-07","article-title":"A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques","volume":"81","author":"Chen","year":"2007","journal-title":"J Virol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1371\/journal.pntd.0000096","article-title":"Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus","volume":"1","author":"Brandler","year":"2007","journal-title":"PLoS Negl Trop Dis."},{"key":"B70","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00705-010-0652-x","article-title":"A plasmid encoding parts of the dengue virus E and NS1 proteins induces an immune response in a mouse model","volume":"155","author":"Mellado-Sanchez","year":"2010","journal-title":"Arch Virol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.virol.2009.10.023","article-title":"Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy","volume":"396","author":"Simmons","year":"2010","journal-title":"Virology."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e377","DOI":"10.1016\/j.ijid.2009.06.017","article-title":"Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use","volume":"14","author":"Vald\u00e9s","year":"2010","journal-title":"Int J Infect Dis"},{"key":"B73","doi-asserted-by":"publisher","first-page":"268","DOI":"10.4110\/in.2011.11.5.268","article-title":"Distinct humoral and cellular immunity induced by alternating prime-boost vaccination using plasmid DNA and live viral vector vaccines expressing the e protein of dengue virus type 2","volume":"11","author":"George","year":"2011","journal-title":"Immune Netw."},{"key":"B74","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1128\/CVI.00382-10","article-title":"The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN-2","volume":"18","author":"Vald\u00e9s","year":"2011","journal-title":"Clin Vaccine Immunol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1038\/cti.2017.24","article-title":"The tetravalent formulation of domain III-capsid proteins recalls memory B- and T-cell responses induced in monkeys by an experimental dengue virus infection","volume":"6","author":"Gil","year":"2017","journal-title":"Clin Transl Immunol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/infdis\/jiq059","article-title":"Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic","volume":"203","author":"Durbin","year":"2011","journal-title":"J Infect Dis."},{"key":"B77","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1016\/j.vaccine.2016.03.108","article-title":"Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold\/DNA vaccine in non-human primates","volume":"34","author":"McBurney","year":"2016","journal-title":"Vaccine"},{"key":"B78","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1016\/j.vaccine.2013.06.079","article-title":"Identifying protective dengue vaccines: guide to mastering an empirical process","volume":"31","author":"Halstead","year":"2013","journal-title":"Vaccine"},{"key":"B79","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00705-015-2681-y","article-title":"Could an experimental dengue virus infection fail to induce solid immunity against homologous viral challenge in non-human primates?","volume":"161","author":"Vald\u00e9s","year":"2016","journal-title":"Arch Virol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"e0004398","DOI":"10.1371\/journal.pntd.0004398","article-title":"Incomplete protection against dengue virus type 2 Re-infection in Peru","volume":"10","author":"Forshey","year":"2016","journal-title":"PLoS Negl Trop Dis."},{"key":"B81","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1586\/erv.13.11","article-title":"Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets","volume":"12","author":"de Cassan","year":"2013","journal-title":"Exp Rev Vaccin."},{"key":"B82","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.immuni.2010.10.004","article-title":"Immunologic basis of vaccine vectors","volume":"33","author":"Liu","year":"2010","journal-title":"Immunity."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e58357","DOI":"10.1371\/journal.pone.0058357","article-title":"The synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever\/dengue virus leads to strong protection against dengue","volume":"8","author":"Azevedo","year":"2013","journal-title":"PLoS ONE."},{"key":"B84","doi-asserted-by":"publisher","first-page":"724","DOI":"10.4269\/ajtmh.2011.10-0436","article-title":"Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans","volume":"85","author":"Qiao","year":"2011","journal-title":"Am J Trop Med Hyg."},{"key":"B85","doi-asserted-by":"publisher","first-page":"5712","DOI":"10.1016\/j.vaccine.2008.08.019","article-title":"Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects","volume":"26","author":"Guy","year":"2008","journal-title":"Vaccine"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s00705-013-1956-4","article-title":"Generation and characterization of potential dengue vaccine candidates based on domain III of the envelope protein and the capsid protein of the four serotypes of dengue virus","volume":"159","author":"Suzarte","year":"2014","journal-title":"Arch Virol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/infdis\/jiv082","article-title":"Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults","volume":"212","author":"Kirkpatrick","year":"2015","journal-title":"J Infect Dis."},{"key":"B88","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1099\/jgv.0.001271","article-title":"A heterologous prime-boost strategy for immunization against Dengue virus combining the Tetra DIIIC subunit vaccine candidate with the TV005 live-attenuated tetravalent vaccine","volume":"100","author":"Vald\u00e9s","year":"2019","journal-title":"J Gen Virol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1093\/infdis\/jiw067","article-title":"A 12-month-interval dosing study in adults indicates that a single dose of the national institute of allergy and infectious diseases tetravalent dengue vaccine induces a robust neutralizing antibody response","volume":"214","author":"Durbin","year":"2016","journal-title":"J Infect Dis."},{"key":"B90","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1093\/infdis\/jis936","article-title":"A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial","volume":"207","author":"Durbin","year":"2013","journal-title":"J Infect Dis."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14760584.2017.1335201","article-title":"A recombinant live attenuated tetravalent vaccine for the prevention of dengue","volume":"16","author":"Guy","year":"2017","journal-title":"Exp Rev Vaccin."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01956\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T12:56:53Z","timestamp":1695128213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01956\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,27]]},"references-count":91,"alternative-id":["10.3389\/fimmu.2019.01956"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.01956","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,27]]},"article-number":"1956"}}